Evotec Revenue and Competitors

Location

N/A

Total Funding

Fintech

Industry

Estimated Revenue & Valuation

  • Evotec's estimated annual revenue is currently $571.5M per year.(i)
  • Evotec's estimated revenue per employee is $91,318
  • Evotec's current valuation is $7B. (January 2022)

Employee Data

  • Evotec has 6258 Employees.(i)
  • Evotec grew their employee count by 3% last year.

Evotec's People

NameTitleEmail/Phone
1
Product Owner & Software Support for the Sample ManagementReveal Email/Phone
2
EVP, ERP Owner & Transformation LeadReveal Email/Phone
3
Sr VP Head NephrologyReveal Email/Phone
4
VPReveal Email/Phone
5
Chief Financial OfficerReveal Email/Phone
6
Chief Scientific OfficerReveal Email/Phone
7
VPReveal Email/Phone
8
Chief Business Officer (partnering, tech, strategy)Reveal Email/Phone
9
Chief Operating OfficerReveal Email/Phone
10
SVP Academic PartnershipsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46850M14500016%$20.2B$539B
Add Company

What Is Evotec?

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,500 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.

keywords:N/A

N/A

Total Funding

6258

Number of Employees

$571.5M

Revenue (est)

3%

Employee Growth %

$7B

Valuation

N/A

Accelerator

Evotec News

2022-03-22 - Evotec SE fiscal year 2021 results: "Setting the Pace" on the ...

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today reported financial results and corporate...

2022-03-22 - Evotec achieves programme designation in neuroscience ...

THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB...

2022-03-22 - Clinical development

Evotec is a fully-integrated drug discovery and development partner, providing a comprehensive source of high quality scientific solutions...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A85286%N/A